tbuckley/cabot-search huggingface dataset:
Simultaneous Mapping of Pan and Sentinel Lymph Nodes for Real-Time Image-Guided Surgery
Authors: Yoshitomo Ashitate, Hoon Hyun, Soon Hee Kim, Jeong Heon Lee, Maged Henary, John V. Frangioni, Hak Soo Choi
Journal: Theranostics (2014)

The resection of regional lymph nodes in the basin of a primary tumor is of paramount importance in surgical oncology.Although sentinel lymph node mapping is now the standard of care in breast cancer and melanoma, over 20% of patients require a completion lymphadenectomy.Yet, there is currently no technology available that can image all lymph nodes in the body in real time, or assess both the sentinel node and all nodes simultaneously.In this study, we report an optical fluorescence technology that is capable of simultaneous mapping of pan lymph nodes (PLNs) and sentinel lymph nodes (SLNs) in the same subject.We developed near-infrared fluorophores, which have fluorescence emission maxima either at 700 nm or at 800 nm.One was injected intravenously for identification of all regional lymph nodes in a basin, and the other was injected locally for identification of the SLN.Using the dual-channel FLARE intraoperative imaging system, we could identify and resect all PLNs and SLNs simultaneously.The technology we describe enables simultaneous, real-time visualization of both PLNs and SLNs in the same subject.
Comparative Analysis of Peritoneum and Tumor Eicosanoids and Pathways in Advanced Ovarian Cancer
Authors: Ralph S. Freedman, Ena Wang, Sonia Voiculescu, Rebecca Patenia, Roland L. Bassett, Michael Deavers, Francesco M. Marincola, Peiying Yang, Robert A. Newman
Journal: Clinical Cancer Research (2007)

Abstract Purpose: To describe the eicosanoid profile and differentially expressed eicosanoid and arachidonic acid pathway genes in tissues from patients with advanced epithelial ovarian cancer (EOC). Experimental Design: We first employed electrospray tandem mass spectrometry to determine tissue-specific concentrations of the eicosanoids prostaglandin E2 (PGE2), the hydroxyeicosatetraenoic acids (12-HETE and 5-HETE), and leukotriene (LTB4), selected for tumor growth potential, and two other bioactive lipids (15-HETE and 13-HODE) with tumor cell proliferation interference potential. The cellular location of eicosanoid activity was identified by immunofluorescence antibody costaining and confocal microscopy. Differential analysis of eicosanoid and arachidonic pathway genes was done using a previously validated cDNA microarray platform. Tissues used included EOC tumor, tumor-free malignant peritoneum (MP), and benign peritoneum (BP) from patients with benign pelvic disease. Results: (a) Eicosanoid products were detected in tumor, MP, and BP specimens. PGE2 levels were significantly elevated in tumors in an overall comparison with MP or BP (P &amp;lt; 0.001). Combined levels of PGE2, 12-HETE, 5-HETE, and LTB4 increased progressively from low to high concentrations in BP, MP, and tumors (P = 0.012). Neither 15-HETE nor 13-HODE showed a significant opposite trend toward levels found in BP. (b) Tissue specimens representing common EOC histotypes showed strong coexpressions of cyclooxygenases (COX-1) and prostaglandin E synthases (PGES-1) on tumor cells, whereas intratumoral or peritumoral MO/MA coexpressed COX-1 and COX-2 and PGES-1 and PGES-2, respectively. (c) cDNA microarray analysis of MP, BP, and tumor showed that a number of eicosanoid and arachidonic acid pathway genes were differentially expressed in MP and BP compared with tumor, except for CYP2J2, which was increased in tumors. Conclusions: Elevated levels of eicosanoid metabolites in tumors and differential expression of eicosanoid and arachidonic acid pathway genes in the peritoneum support the involvement of bioactive lipids in the inflammatory tumor environment of EOC.
General practitioners with special clinical interests
Authors: R. Rosen
Journal: BMJ (2003)

<b>Background:</b> Obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD) are linked with microvascular changes. Retinal microvasculature can be examined in a direct noninvasive way. <b>Aim:</b> The aim was to evaluate tortuosity of the retinal vessels in patients with COPD, OSA, and overlap syndrome. <b>Patients and Methods:</b> A total of 60 participants were included: 15 patients with OSA, 15 patients with COPD, 15 patients with COPD-OSA overlap syndrome, and 15 matched controls. All participants underwent slit lamp examination with digital retinal photography, polysomnography, arterial blood gases, spirometry, Epworth sleepiness scale, and STOP-BANG questionnaires. <b>Results:</b> Tortuosity of most retinal vessels was higher in all patient groups when compared with the control group, and tortuosity was more marked in the overlap syndrome group. There was a negative correlation between tortuosity of retinal vessels and PO2, O2 saturation, and minimum O2 saturation, and a positive correlation with PCO2, apnea hypopnea index, O2 desaturation index, body-mass index (BMI), and smoking index. <b>Conclusion:</b> Retinal vascular tortuosity occurs in OSA, COPD, and overlap syndrome. Retinal vascular tortuosity is correlated with arterial blood gases parameters, polysomnographic findings, smoking index, and BMI.
A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients
Authors: Vincent G. Bain, Kelly D. Kaita, Eric M. Yoshida, Mark G. Swain, E. Jenny Heathcote, Avidan U. Neumann, Michele Fiscella, Ren Yu, Blaire L. Osborn, Patrick W. Cronin, William W. Freimuth, John G. McHutchison, G. Mani Subramanian
Journal: Journal of Hepatology (2006)
Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells
Authors: Craig L. Slingluff, Gina R. Petroni, Galina V. Yamshchikov, Donna L. Barnd, Shannon Eastham, Holly Galavotti, James W. Patterson, Donna H. Deacon, Sarah Hibbitts, David Teates, Patrice Y. Neese, William W. Grosh, Kimberly A. Chianese-Bullock, Elizabeth M.H. Woodson, Catherine J. Wiernasz, Priscilla Merrill, Jennifer Gibson, Maureen Ross, Victor H. Engelhard
Journal: Journal of Clinical Oncology (2003)

To determine clinical and immunologic responses to a multipeptide melanoma vaccine regimen, a randomized phase II trial was performed.Twenty-six patients with advanced melanoma were randomly assigned to vaccination with a mixture of four gp100 and tyrosinase peptides restricted by HLA-A1, HLA-A2, and HLA-A3, plus a tetanus helper peptide, either in an emulsion with granulocyte-macrophage colony-stimulating factor (GM-CSF) and Montanide ISA-51 adjuvant (Seppic Inc, Fairfield, NJ), or pulsed on monocyte-derived dendritic cells (DCs). Systemic low-dose interleukin-2 (Chiron, Emeryville, CA) was given to both groups. T-lymphocyte responses were assessed, by interferon gamma ELIspot assay (Chiron, Emeryville, CA), in peripheral-blood lymphocytes (PBLs) and in a lymph node draining a vaccine site (sentinel immunized node [SIN]).In patients vaccinated with GM-CSF in adjuvant, T-cell responses to melanoma peptides were observed in 42% of PBLs and 80% of SINs, but in patients vaccinated with DCs, they were observed in only 11% and 13%, respectively. The overall immune response was greater in the GM-CSF arm (P <.02). Vitiligo developed in two of 13 patients in the GM-CSF arm but in no patients in the DC arm. Helper T-cell responses to the tetanus peptide were detected in PBLs after vaccination and correlated with T-cell reactivity to the melanoma peptides. Objective clinical responses were observed in two patients in the GM-CSF arm and one patient in the DC arm. Stable disease was observed in two patients in the GM-CSF arm and one patient in the DC arm.The high frequency of cytotoxic T-lymphocyte responses and the occurrence of clinical tumor regressions support continued investigation of multipeptide vaccines administered with GM-CSF in adjuvant.
IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus
Authors: N. Bassi, A. Ghirardello, M. Blank, S. Zampieri, P. Sarzi-Puttini, A. Mantovani, Y. Shoenfeld, A. Doria
Journal: Annals of the Rheumatic Diseases (2010)

To evaluate the prevalence and correlates of anti-pentraxin 3 (PTX3) antibodies in systemic lupus erythematosus (SLE).Serum samples from 130 patients with SLE, 130 age- and sex-matched healthy subjects and 130 patients with other autoimmune rheumatic diseases (oARD) were analysed by home-made ELISAs using as substrate human recombinant PTX3 and two peptides, PTX3_1 and PTX3_2, obtained from the complete protein, identified as potential antigenic sites using the Lasergene DNA program (DNA Star). Inhibition tests were performed to evaluate potential interferences between bovine serum albumin or C-reactive protein and anti-PTX3 or anti-PTX3 peptides, and between antigens and antibodies. Statistical analysis was performed using receiving operating characteristics curves, the Fisher exact test, two-tailed t test and Pearson correlations.Patients with SLE had higher levels and prevalence of anti-PTX3, anti-PTX3_1 and anti-PTX3_2 antibodies than patients with oARD or healthy controls (p<0.001 for all). No differences were observed between patients with oARD and healthy controls. A correlation was found between anti-PTX3 and anti-PTX3_2 antibodies (r=0.615, p<0.001). No association was observed between these antibodies and disease activity. Univariate and multivariate analyses showed that anti-PTX3 and anti-PTX3_2 antibody levels and prevalence were higher in patients without glomerulonephritis and in patients positive for antiphospholipid antibody. All inhibition tests were negative apart from PTX3 against anti-PTX3 antibody or, to a lesser extent, against anti-PTX3_2 antibody, and PTX3_2 against anti-PTX3_2 antibody, all in a dose-dependent manner.Anti-PTX3 antibodies are significantly prevalent in patients with SLE where they might provide protection from renal involvement. The antigenic properties of PTX3_2 peptide are similar to those of PTX3, suggesting its potential use in further analyses.
The potential use of xylitol in glucose-6-phosphate dehydrogenase deficiency anemia
Authors: Y. M. Wang, J. H. Patterson, J. Van Eys
Journal: Journal of Clinical Investigation (1971)

NADP-linked xylitol dehydrogenase has been found to be present in human red blood cells. This enzyme activity is normal in most glucose-6-phosphate dehydrogenase (G6PD)-deficient red cells. Xylitol was explored as a potential agent for treatment of hemolysis in patients with G6PD-deficiency. Intracellular GSH (glutathione, reduced) was first converted to its oxidized form by incubation of the erythrocytes with acetylphenylhydrazine or by pretreatment with methyl phenyldiazenecarboxylate. The addition of 0.15 M xylitol was shown to be more effective than 0.15 M glucose in maintaining the levels of GSH in G6PD-deficient red cells during such oxidative challenge. Rabbit erythrocytes contain less activity of G6PD and glutathione reductase compared with the normal human adult values, but have an active xylitol dehydrogenase. The rabbit erythrocyte is sensitive to acetylphenylhydrazine and primaquine phosphate. In both in vivo and in vitro experiments, xylitol was found to partially prevent acetylphenylhydrazine induced acute hemolysis of the rabbit red cell and GSH content was found to be preserved. The intravenous injection of xylitol (0.5 g/kg body weight per 6 hr) for 6 days, seemed to be nontoxic to the animal. The results suggest that xylitol should be further investigated as an agent for the treatment of G6PD-deficient patients during acute hemolytic episodes.
Dyspepsia: management guidelines for the millennium
Authors: N J Talley
Journal: Gut (2002)

The annual prevalence of dyspepsia in Western countries is approximately 25%, and the condition accounts for 2–5% of all primary care consultations, yet optimal management remains a subject of considerable debate. Some of the outstanding issues and considerations in the management of dyspepsia are discussed, providing an overview of current thinking and recommendations on patient management by primary care physicians and specialists.
Blood pressure in prospective population based cohort of newborn and infant twins
Authors: R S Levine, C H Hennekens, M J Jesse
Journal: BMJ (1994)

<h3>Abstract</h3> <b>Objective</b> : To describe blood pressure in twins during infancy. <b>Design</b> : Prospective study of cohort of twins. <b>Setting</b> : Teaching hospital in Florida. <b>Subjects</b> : 166 viable twin pairs born between July 1976 and December 1989. <b>Main outcome measures</b> : Blood pressure and body weight at birth, at 14 days, and at 1, 3, 6, 9, and 12 months. <b>Results</b> : Both systolic and diastolic pressure correlated with body weight throughout infancy (at birth r=0.41, P &lt;0.001 and r=0.42, P&lt;0.001 respectively; at 1 year r=0.23, P&lt;0.001 and r=0.26, P &lt;0.001 respectively). In infants weighing &lt;1500 g at birth mean blood pressure rose from about 45/25 mm Hg to 101/55 mm Hg from birth to the age of 1 year, while in infants weighing &gt;3000 g at birth it rose from 63/39 mm Hg to 100/61 mm Hg; corresponding mean body weights at 1 year were 7.86 kg and 9.88 kg. Differences in birth weight within pairs of monozygotic twins were negatively correlated with such differences in systolic blood pressure at 1 year (r equal -0.37, P &lt;0.01). <b>Conclusions</b> : Blood pressure and body weights in twins showed strongly positive but generally declining correlations throughout infancy. Twins of lower birth weight showed a more rapid rate of rise in blood pressure during infancy. At 1 year the catch up in blood pressure exceeded that in body weight. Greater differences in birth weights between monozygotic twins were associated with smaller differences in systolic blood pressure at 1 year, suggesting that intrauterine environmental factors related to birth weight are important in determining blood pressure in infancy.
Highly Activated T-Cell Receptor AV2S3<sup>+</sup> CD4<sup>+</sup> Lung T-Cell Expansions in Pulmonary Sarcoidosis
Authors: KIANOOSH KATCHAR, JAN WAHLSTRÖM, ANDERS EKLUND, JOHAN GRUNEWALD
Journal: American Journal of Respiratory and Critical Care Medicine (2001)

Sarcoidosis is a systemic disorder of unknown origin, primarily affecting the lungs. The granulomatous inflammation is driven by the interplay between various molecules and cells, including T cells. Previously, our group reported a close correlation between lung-restricted T-cell receptor (TCR) AV2S3 CD4-positive T-cell expansions and HLA-DR17 in active sarcoidosis. The aim of this study was to characterize phenotypically such AV2S3 lung T cells, to obtain more information about the state of activation of this intriguing T-cell subset. Bronchoalveolar lavage (BAL) was performed on sarcoidosis patients with active disease and on healthy control subjects (HC). The expression of activation and subset markers was evaluated and compared between BAL AV2S3-positive and AV2S3-negative T cells of patients with lung-restricted AV2S3 T-cell expansions, and between BAL and peripheral blood lymphocytes (PBL) of patients and HC. The frequency of cells expressing activation markers CD26, CD28, CD69, and HLA-DR was enhanced in AV2S3-positive versus AV2S3-negative BAL CD4+ T-cell subsets. In contrast, CD25 (Il-2R) and CD27 were expressed at lower levels by the AV2S3-positive CD4+ lung T cells. Our data confirm a substantial activation of BAL CD4+ T cells of patients with sarcoidosis. Furthermore, the AV2S3 CD4-positive lung cells display a pattern of activation markers, suggesting that they are significantly more activated compared with lung CD4+ T cells expressing other TCR V gene segments as well as compared with BAL CD4+ T cells of HC. These results support our hypothesis of an ongoing and selective stimulation of AV2S3 T cells by a specific antigen and the participation of this subset in the inflammatory process in the lungs of patients with sarcoidosis.
Quantification of risk factors for herpes zoster: population based case-control study
Authors: Harriet J Forbes, Krishnan Bhaskaran, Sara L Thomas, Liam Smeeth, Tim Clayton, Sinéad M Langan
Journal: BMJ (2014)

To quantify the effects of possible risk factors for herpes zoster at different ages.Case-control study.UK Clinical Practice Research Datalink primary care data.144 959 adults diagnosed with zoster between 2000 and 2011; 549,336 age, sex, and practice matched controls.Conditional logistic regression was used to generate adjusted odds ratios to estimate the strength of association of each potential risk factor with zoster and assess effect modification by age.The median age of the cases and controls was 62 years. Factors associated with increased risk of zoster included rheumatoid arthritis (3111 (2.1%) v 8029 (1.5%); adjusted odds ratio 1.46, 99% confidence interval 1.38 to 1.55), inflammatory bowel disease (1851 (1.3%) v 5118 (0.9%); 1.36, 1.26 to 1.46), chronic obstructive pulmonary disease (6815 (4.7%) v 20 201 (3.7%); 1.32, 1.27 to 1.37), asthma (10 243 (7.1%) v 31 865 (5.8%); 1.21, 1.17 to 1.25), chronic kidney disease (8724 (6.0%) v 29 437 (5.4%); 1.14, 1.09 to 1.18), and depression (6830 (4.7%) v 22 052 (4.0%); 1.15, 1.10 to 1.20). Type 1, but not type 2, diabetes showed some association with zoster (adjusted odds ratio 1.27, 1.07 to 1.50). The relative effects of many assessed risk factors were larger in younger patients. Patients with severely immunosuppressive conditions were at greatest risk of zoster-for example, patients with lymphoma (adjusted odds ratio 3.90, 3.21 to 4.74) and myeloma (2.16, 1.84 to 2.53), who are not eligible for zoster vaccination.A range of conditions were associated with increased risk of zoster. In general, the increased risk was proportionally greater in younger age groups. Current vaccines are contraindicated in people at the greatest risk of zoster, highlighting the need for alternative risk reduction strategies in these groups.
Intrathecal delivery of CNTF using encapsulated genetically modifiedxenogeneic cells in amyotrophic lateral sclerosis patients
Authors: Patrick Aebischer, Myriam Schluep, Nicole Déglon, Jean-Marc Joseph, Lorenz Hirt, Bruno Heyd, Moses Goddard, Joseph P. Hammang, Anne D. Zurn, Ann C. Kato, Franco Regli, E. Edward Baetge
Journal: Nature Medicine (1996)
Sebaceous tumours contain a subpopulation of cells expressing the keratin 15 stem cell marker
Authors: R. Bieniek, A.J.F. Lazar, C. Photopoulos, S. Lyle
Journal: British Journal of Dermatology (2006)

Journal Article Sebaceous tumours contain a subpopulation of cells expressing the keratin 15 stem cell marker Get access R. Bieniek, R. Bieniek Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, U.S.A. *Departments of Pathology and Dermatology, University of Texas M.D. Anderson Cancer Center, Houston, TX, U.S.A. †Department of Cancer Biology, University of Massachusetts Medical School, 364 Plantation Street, LRB 411, Worcester, MA 01605, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar A.J.F. Lazar, A.J.F. Lazar Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, U.S.A. *Departments of Pathology and Dermatology, University of Texas M.D. Anderson Cancer Center, Houston, TX, U.S.A. †Department of Cancer Biology, University of Massachusetts Medical School, 364 Plantation Street, LRB 411, Worcester, MA 01605, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar C. Photopoulos, C. Photopoulos Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, U.S.A. *Departments of Pathology and Dermatology, University of Texas M.D. Anderson Cancer Center, Houston, TX, U.S.A. †Department of Cancer Biology, University of Massachusetts Medical School, 364 Plantation Street, LRB 411, Worcester, MA 01605, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar S. Lyle S. Lyle Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, U.S.A. *Departments of Pathology and Dermatology, University of Texas M.D. Anderson Cancer Center, Houston, TX, U.S.A. †Department of Cancer Biology, University of Massachusetts Medical School, 364 Plantation Street, LRB 411, Worcester, MA 01605, U.S.A. Correspondence: Stephen Lyle. E‐mail: stephen.lyle@umassmed.edu Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 156, Issue 2, 1 February 2007, Pages 378–380, https://doi.org/10.1111/j.1365-2133.2006.07623.x Published: 01 February 2007
Serum adiponectin levels and tissue expression of adiponectin receptors are associated with risk, stage, and grade of colorectal cancer
Authors: Spyros P. Gialamas, Eleni Th. Petridou, Sofia Tseleni-Balafouta, Themistoklis N. Spyridopoulos, Ioannis L. Matsoukis, Agathi Kondi-Pafiti, George Zografos, Christos S. Mantzoros
Journal: Metabolism (2011)
A Role for Complement in Feedback Enhancement of Antibody Responses by IgG3
Authors: Teresita Díaz de Ståhl, Jörgen Dahlström, Michael C. Carroll, Birgitta Heyman
Journal: The Journal of Experimental Medicine (2003)

IgG1, IgG2a, and IgG2b, passively administered with soluble Ags, enhance specific Ab responses. The effect of IgG3 in this type of feedback regulation has not been studied previously. We immunized mice with trinitrophenyl (TNP)-coupled carrier proteins (bovine serum albumin [BSA] or ovalbumin [OVA]) alone or complexed to monoclonal TNP-specific IgG3. The carrier-specific Ab responses were enhanced by several hundred-fold by IgG3. Enhancement was significantly impaired in mice depleted of complement factor C3 and in mice lacking complement receptors 1 and 2 (Cr2−/−). In contrast, mice lacking the common Fc-receptor gamma chain (FcRγ−/−), resulting in reduced expression of FcγRI and lack of FcγRIII, and mice lacking FcγRIIB (FcγRIIB−/−), responded equally well to immunization with IgG3-complexed Ag as wild-type controls. These findings demonstrate that IgG3 can induce feedback enhancement and that IgG3, in analogy with IgM, uses the complement system for this function.